Sept 21 (Reuters) - Xvivo Perfusion AB XVIVO.ST :
* STRATEGY FOR PERIOD 2023 - 2027 HAS BEEN UPDATED AND
BUILDS ON
FIVE FOCUS AREAS; MARKET LEADER ABDOMINAL; CHANGING PARADIGM OF
HEART PRESERVATION; BECOMING PREFERRED PARTNER IN TRANSPLANT
PROCESS; ACCELERATING MARKET LEADERSHIP LUNGS; AND NEW MARKET
EXPANSION
* SHARPENS ITS PROFITABILITY AMBITIONS AND SHALL REACH AN
EBIT-MARGIN OF AT LEAST 20 % AND AN EBITDA-MARGIN OF AT LEAST 30
% DURING STRATEGY PERIOD
Source text for Eikon: ID:nMFNbCKdZ
Further company coverage: XVIVO.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))